New combo therapy shows promise for First-Line CLL treatment
Disease control
Completed
This phase 2 trial tested a combination of bendamustine and rituximab (BR) followed by venetoclax in 42 people with untreated chronic lymphocytic leukemia (CLL). The goal was to see how many patients responded to the full 15-month treatment. Venetoclax is an oral drug that target…
Phase: PHASE2 • Sponsor: Nicole Lamanna • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC